Clinical trials: CAR-T Cell Immunotherapy
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22 CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients.
- Trial name
- NCT05797948
- Testing
- Obinutuzumab, Zanubrutinib, Lenalidomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Neuroblastoma, Ganglioneuroblastoma
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cells obtained directly from the patient, which can be genetically…
- Trial name
- NCT02311621
- Testing
- Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Seattle Children's Hospital
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood.
- Conditions
- Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
- Trial name
- IMAGINE (NCT05138458)
- Testing
- MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Myeloid Therapeutics
Pancreatic Cancer, Renal Cell Cancer
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person.
- Conditions
- Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma
- Trial name
- NCT02830724
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
The study is an early, open, single-centered trial.
- Trial name
- NCT03825718
- Testing
- GC007F
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
Background: About 23,000 people die from B-cell cancers in the US each year. These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells.
- Conditions
- Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
- Trial name
- NCT05797233
- Testing
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Membranous Nephropathy
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.
- Trial name
- NCT07266181
- Testing
- All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Gastric Cancer, Breast Cancer
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1.
- Conditions
- Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT05483491
- Testing
- KK-LC-1 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Christian Hinrichs
Colorectal Neoplasms
Tailoring Treatment in Colorectal Cancer
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients.
- Trial name
- TargetCRC (NCT05401318)
- Testing
- Tumor tissue sampling for organoid development
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- University Hospital, Akershus
Leukemia
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
- Trial name
- NCT04100187
- Testing
- Anti-CD19-CAR
- Volunteers
- 100 people
- Sponsor
- Kecellitics Biotech Company Ltd
Diffuse Large B Cell Lymphoma
A Combination Study of CAR-T Therapy in r/r B-NHL
In registry studies of CAR-T products that have been marketed globally, patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) have been enrolled to receive CAR-T infusion in combination with tyrosine…
- Trial name
- NCT05871684
- Testing
- BTK inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Ruijin Hospital
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia
- Trial name
- NCT02159495
- Testing
- cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Lymphoma Leukemia
Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
B cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-Hodgkin's lymphomas (NHL), lymphoblastic leukemias (ALL) and chronic lymphocytic leukemias (CLL).
- Trial name
- NCT03811457
- Testing
- Welgenaleucel
- Where
- China
- Volunteers
- 9 people
- Sponsor
- UWELL Biopharma
Multiple Myeloma
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple…
- Trial name
- EVOLVE (NCT03430011)
- Testing
- JCARH125, JCARH125 + anakinra
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Recurrent B-Cell Tumor, Refractory B-Cell Tumor
Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia
Objectives: The purpose of this study is to evaluate the safety and prognosis of New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T (nCAR19-T) Cells in the treatment of recurrent/refractory B-cell tumor and the…
- Trial name
- NCT02644655
- Testing
- CD19-specific chimeric antigen receptor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Military Medical University
Leukemia
Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies
Immunotherapy is a promising therapeutic approach for patients with cancers. Patients with acute lymphoblastic leukemia (ALL) experiencing early relapse less than 18 months from diagnosis had very poor prognosis with 5-year…
- Trial name
- NCT03624686
- Testing
- peripheral blood
- Where
- Taiwan
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma, Immunotherapy
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation
- Trial name
- NCT03198546
- Testing
- GPC3 and/or TGFβ targeting CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT05131763
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Fudan University
Anti-cancer Cell Immunotherapy, T Cell and NK Cell
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK)…
- Trial name
- NCT03882840
- Testing
- ITNK cell therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University